Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors

FAZIO, Nicola, Jean-Francois MARTINI, Adina E. CROITORU, Michael SCHENKER, Sherry LI, Brad ROSBROOK, Kathrine FERNANDEZ, Jiří TOMÁŠEK, Espen THIIS-EVENSEN, Matthew KULKE and Eric RAYMOND. Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. Future Oncology. London: Future Medicine Ltd., 2019, vol. 15, No 17, p. 1997-2007. ISSN 1479-6694. Available from: https://dx.doi.org/10.2217/fon-2018-0934.

Basic information

• Original name: Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors
• Authors: FAZIO, Nicola (380 Italy), Jean-Francois MARTINI (840 United States of America), Adina E. CROITORU (642 Romania), Michael SCHENKER (642 Romania), Sherry LI (840 United States of America), Brad ROSBROOK (840 United States of America), Kathrine FERNANDEZ (840 United States of America), Jiří TOMÁŠEK (203 Czech Republic, belonging to the institution), Espen THIIS-EVENSEN (578 Norway), Matthew KULKE (840 United States of America) and Eric RAYMOND (250 France).
• Edition: Future Oncology, London, Future Medicine Ltd. 2019, 1479-6694.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30204 Oncology
• Country of publisher: United Kingdom of Great Britain and Northern Ireland
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 2.660
• RIV identification code: RIV/00216224:14110/19:00112848
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.2217/fon-2018-0934
• UT WoS: 000474879700006
• Keywords in English: biomarkers; efficacy; pancreatic neuroendocrine tumor; sunitinib; VEGF
• Tags: 14110811, rivok
• Tags: International impact, Reviewed

Abstract

Aim: Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib. Patients & methods: Kaplan-Meier and Cox proportional hazards models were used to analyze the association between SNPs and survival outcomes using data from a sunitinib Phase IV (genotyped, n = 56) study. Fisher's exact test was used to analyze objective response rate and genotype associations. Results: After multiplicity adjustment, progression-free and overall survivals were not significantly correlated with SNPs; however, a higher objective response rate was significantly associated with IL1B rs16944 G/A versus G/G (46.4 vs 4.5%; p = 0.001). Conclusion: IL1B SNPs may predict treatment response in patients with pancreatic neuroendocrine tumors. VEGF pathway SNPs are potentially associated with survival outcomes.